Heska Corporation Announces New Allergy Therapy Products
The Heska Corporation, which is in the business of selling advanced veterinary diagnostic and specialty products, announced an expansion of its allergy franchise via a brand new technology.
This allergic treatment advancement will support Heska’s production for both sublingual and subcutaneous immunotherapy at the company’s Des Moines, Iowa, facility in addition to augmenting their proprietary allergy treatment offerings.
Michael McGinley, President and Chief Operating Officer of Heska, shared, “As the veterinary industry leader in allergy testing and treatment, Heska now complements and expands this part of our business with more complete treatment options. Sublingual therapy offers a convenient alternative to subcutaneous injection, thereby enhancing the likelihood of pet owner compliance. Furthermore, we worked diligently in 2011 to move our allergy immunotherapy manufacturing to our Des Moines facility and the addition of this product opportunity enhances those economic benefits. It has been estimated that 10-15% of dogs are affected by allergic disease, and this expanded commitment to our allergy franchise is consistent with our strategy of offering valuable products in important areas of veterinary medicine."
The founder of Dr. Mary Morris and Associates, LLC, Mary Morris, MD, shared that Heska’s animal allergy expertise will complement their own human breakthroughs in the allergy department for both testing and treatment. Using the intellectual property of Dr. Mary Morris and Associates, LLC, it is expected that pets suffering from allergies will have viable treatment options. Morris’s company developed sublingual immunotherapy to expand treatment options for allergic diseases in people and animals.
Heska revealed that product testing has taken place over the last three years, with plans to introduce product to coincide with the busy allergy season in pets.
To learn more about Heska, visit www.heska.com.
No comments posted...